Abstract #3358

Efficacy of Gadoterate Meglumine enhanced MRA in evaluating thoracic aortic aneurysm and comparison with Gadobutrol enhanced MRA

Kaitlin Crawford¹, Ali Serhal², Olivia D. Reese², Pascale Aouad², Matthew Barrett², Monica Korell², Amir Rahsepar², Monda Shehata², Ahmadreza Ghasemiesfe², Jeremy Collins², and James Carr^2,3

¹University of Notre Dame, South Bend, IN, United States, ²Northwestern University, Chicago, IL, United States, ³Knight Family Professor of Cardiac Imaging, Chicago, IL, United States

Contrast enhanced Magnetic resonance imaging plays an important role in the diagnosis and follow-up of patients with thoracic aortic aneurysm (TAA). Gadoterate Meglumine, which has recently become available in the US, is considered one of the safer gadolinium contrast agents with respect to tissue deposition and NSF, due its macrocyclic structure. In this study, we compare the qualitative image quality and quantitative aortic dimensions of Gadoterate Meglumine enhanced MRA and compare it to Gadobutrol enhanced MRA for evaluation of thoracic aortic disease. These preliminary results showed that Gadoterate Meglumine enhanced MRA has comparable image quality to Gadobutrol enhanced MRA and excellent correlation with respect to aortic diameter measurements.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.